Aldeyra Therapeutics(ALDX)
Search documents
Aldeyra Therapeutics(ALDX) - 2023 Q2 - Quarterly Report
2023-08-02 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36332 ALDEYRA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 20-1968197 (State or Other Ju ...
Aldeyra Therapeutics(ALDX) - 2023 Q1 - Quarterly Report
2023-05-03 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36332 ALDEYRA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 20-1968197 (State or Other J ...
Aldeyra Therapeutics(ALDX) - 2022 Q4 - Earnings Call Transcript
2023-03-09 15:45
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Q4 2022 Earnings Conference Call March 9, 2023 8:00 AM ET Company Participants Bruce Greenberg - Interim Chief Financial Officer Todd Brady - President and Chief Executive Officer Conference Call Participants Marc Goodman - SVB Securities Yigal Nochomovitz - Citigroup Justin Kim - Oppenheimer & Co. Catherine Novack - Jones Research Yale Jen - Laidlaw & Company Operator Ladies and gentlemen, thank you for standing by, and welcome to the Aldeyra Therapeutics Full Year ...
Aldeyra Therapeutics(ALDX) - 2022 Q4 - Annual Report
2023-03-08 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission file number 001-36332 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 20-1968197 (State or Other Jurisdiction ...
Aldeyra Therapeutics (ALDX) Investor Presentation - Slideshow
2023-03-02 18:14
February 2023 CORPORATE OVERVIEW Innovative Therapeutics to Treat Immune-Mediated Diseases Nasdaq: ALDX © Aldeyra Therapeutics, Inc. 2023 Disclaimers and Forward-Looking Statements ...
Aldeyra Therapeutics(ALDX) - 2022 Q3 - Earnings Call Transcript
2022-11-10 18:40
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Q3 2022 Earnings Conference Call November 10, 2022 8:00 AM ET Company Participants Bruce Greenberg - Interim Chief Financial Officer Todd Brady - President and Chief Executive Officer Conference Call Participants Marc Goodman - SVB Securities Justin Kim - Oppenheimer Yale Jen - Laidlaw & Co. Catherine Novack - Jones Research Operator Ladies and gentlemen, thank you for standing by and welcome to the Aldeyra Therapeutics Third Quarter 2022 Financial Results Conference ...
Aldeyra Therapeutics(ALDX) - 2022 Q2 - Earnings Call Transcript
2022-08-05 18:01
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Q2 2022 Earnings Conference Call August 5, 2022 8:00 AM ET Company Participants Bruce Greenberg - Interim Chief Financial Officer Todd Brady - President & Chief Executive Officer Conference Call Participants Catherine Novack - Jones Research Yigal Nochomovitz - Citigroup Kelly Shi - Jefferies Tom Shrader - BTIG Justin Kim - Oppenheimer & Co. Yale Jen - Laidlaw & Company Operator Ladies and gentlemen, thank you for standing by and welcome to the Aldeyra Therapeutics S ...